Skip to content

CG Oncology CGON Return on assets

Return on assets at other companies

Pfizer logo
PfizerPFE
4.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
10.7%-1.3pp
Gilead Sciences logo
Gilead SciencesGILD
16.4%+5.8pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-179.8%+218pp
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-59.7%-8.2pp
Tango Therapeutics logo
Tango TherapeuticsTNGX
-30.2%-5.5pp

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%
Enterprise value$5.36B+212%
P/S1,062.4×-1,596×

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Calculated from CG Oncology’s reported figures.

Based on trailing twelve months.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's return on assets?
CG Oncology (CGON) reported return on assets of -20% in Q1 2026.
How has CG Oncology's return on assets changed year-over-year?
CG Oncology's return on assets decreased by 24.1% year-over-year, from -16.1% to -20%.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.